비혈관 중추현훈의 약물치료 = Medical Treatment of Nonvascular Central Vertigo

다국어 초록 (Multilingual Abstract)

Central vertigo is the common symptom resulting from abnormalities in the central nervous system, caused by various diseases, which include neurodegenerative, vascular, inflammation, infection, tumor, paraneoplastic, toxic, or metabolic disorders. Since the treatment of central vertigo depends on the causes, an accurate diagnosis should be preceded the treatment through a detailed neurotologic examination and laboratory evaluation. Also, it is important to identify and document the neurologic findings accompanied by central vertigo, because some medication focuses on the ocular motor abnormalities as nystagmus or saccadic intrusion.
Here, we will review the medical treatment for central vertigo.

참고문헌 (Reference)

1 Strupp M, "Vestibular paroxysmia : diagnostic criteria" 26 : 409-415, 2016

2 Lempert T, "Vestibular migraine : diagnostic criteria : consensus document of the Bárány Society and the International Headache Society" 84 : 511-516, 2013

3 Strupp M, "Treatment of vestibular paroxysmia with lacosamide" 9 : 539-541, 2019

4 Byun YJ, "Treatment of vestibular migraine : a systematic review and metaanalysis" 131 : 186-194, 2021

5 Strupp M, "Treatment of downbeat nystagmus with 3, 4-diaminopyridine : a placebo-controlled study" 61 : 165-170, 2003

6 Gandini J, "The neurological update : therapies for cerebellar ataxias in 2020" 267 : 1211-1220, 2020

7 Formeister EJ, "The epidemiology of vestibular migraine : a population-based survey study" 39 : 1037-1044, 2018

8 Tsunemi T, "The effect of 3, 4-diaminopyridine on the patients with hereditary pure cerebellar ataxia" 292 : 81-84, 2010

9 Lee WJ, "The c-Abl inhibitor, nilotinib, as a potential therapeutic agent for chronic cerebellar ataxia" 309 : 82-87, 2017

10 Lei LF, "Safety and efficacy of valproic acid treatment in SCA3/MJD patients" 26 : 55-61, 2016

11 Furman JM, "Rizatriptan reduces vestibular-induced motion sickness in migraineurs" 12 : 81-88, 2011

12 Romano S, "Riluzole in patients with hereditary cerebellar ataxia : a randomised, double-blind, placebo-controlled trial" 14 : 985-991, 2015

13 Salviz M, "Propranolol and venlafaxine for vestibular migraine prophylaxis : a randomized controlled trial" 126 : 169-174, 2016

14 Popkirov S, "Persistent postural-perceptual dizziness(PPPD) : a common, characteristic and treatable cause of chronic dizziness" 18 : 5-13, 2018

15 Staab JP, "Persistent postural-perceptual dizziness" 40 : 130-137, 2020

16 Shaikh A G, "Oculopalatal tremor explained by a model of inferior olivary hypertrophy and cerebellar plasticity" 133 (133): 923-940, 2010

17 Nerrant E, "Gabapentin and memantine for treatment of acquired pendular nystagmus : effects on visual outcomes" 40 : 198-206, 2020

18 Lepcha A, "Flunarizine in the prophylaxis of migrainous vertigo : a randomized controlled trial" 271 : 2931-2936, 2014

19 Eggers SDZ, "Episodic spontaneous dizziness" 27 : 369-401, 2021

20 N euhauser HK, "Epidemiology of vertigo" 20 : 40-46, 2007

21 Strupp M, "Effects of acetyl-DL-leucine in patients with cerebellar ataxia : a case series" 260 : 2556-2561, 2013

22 Shaikh AG, "Effects of 4-aminopyridine on nystagmus and vestibulo-ocular reflex in ataxia-telangiectasia" 260 : 2728-2735, 2013

23 Staab JP, "Diagnostic criteria for persistent postural-perceptual dizziness(PPPD) : consensus document of the committee for the Classification of Vestibular Disorders of the Bárány Society" 27 : 191-208, 2017

24 Sobue I, "Controlled trial of thyrotropin releasing hormone tartrate in ataxia of spinocerebellar degenerations" 61 : 235-248, 1983

25 Zesiewicz TA, "Comprehensive systematic review summary:treatment of cerebellar motor dysfunction and ataxia. Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology" 90 : 464-471, 2018

26 Staab JP, "Chronic subjective dizziness" 18 : 1118-1141, 2012

27 Zwergal A, "Cerebellar dizziness and vertigo : etiologies, diagnostic assessment, and treatment" 40 : 87-96, 2020

28 Choi JY, "Central vertigo" 31 : 81-89, 2018

29 Strupp M, "Aminopyridines for the treatment of neurologic disorders" 7 : 65-76, 2017

30 Zwergal A, "Advances in pharmacotherapy of vestibular and ocular motor disorders" 20 : 1267-1276, 2019

31 Starck M, "Acquired pendular nystagmus in multiple sclerosis : an examinerblind cross-over treatment study of memantine and gabapentin" 257 : 322-327, 2010

32 Bremova T, "Acetyl-dl-leucine in Niemann-Pick type C : a case series" 85 : 1368-1375, 2015

33 Schniepp R, "Acetyl-DL-leucine improves gait variability in patients with cerebellar ataxia : a case series" 3 : 8-, 2016

34 Strupp M, "A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias" 77 : 269-275, 2011

35 Bayer O, "A randomized doubleblind, placebo-controlled, cross-over trial(Vestparoxy)of the treatment of vestibular paroxysmia with oxcarbazepine" 265 : 291-298, 2018

36 Claassen J, "A randomised double-blind, cross-over trial of 4-aminopyridine for downbeat nystagmus : effects on slowphase eye velocity, postural stability, locomotion and symptoms" 84 : 1392-1399, 2013

37 Kalla R, "4-aminopyridine restores vertical and horizontal neural integrator function in downbeat nystagmus" 130 (130): 2441-2451, 2007